At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
trospium chloride +2 moredrug
Likely dose
trospium chloride 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
In Brief
A Phase 4 clinical trial evaluating trospium chloride, oxybutynin IR, and 1 other intervention for Overactive Bladder. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory impairment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedAug 2010
Primary CompletionMar 2011
TodayJul 2026
First PostedAug 10, 2010
Enrollment StartAug 1, 2010
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.9 years ago
Interventions
trospium chloridedrug
trospium chloride (60mg) once daily for 10 days
oxybutynin IRdrug
oxybutynin IR (5 mg) three times daily for 2 days
oxybutynin IR placebodrug
oxybutynin IR placebo three times daily for 2 days